S Mocellin

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi Coinhibitory molecules in cancer biology and therapy
    Simone Mocellin
    Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Cytokine Growth Factor Rev 24:147-61. 2013
  2. ncbi Vitamin D and cancer: deciphering the truth
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Biochim Biophys Acta 1816:172-8. 2011
  3. ncbi Telomerase and the search for the end of cancer
    Simone Mocellin
    Department of Surgery, Oncology, and Gastroenterology, School of Medicine, University of Padova, 35100 Padova, Italy
    Trends Mol Med 19:125-33. 2013
  4. ncbi Circumventing melanoma chemoresistance by targeting DNA repair
    S Mocellin
    Department Oncological and Surgical Sciences, University of Padova, Italy
    Curr Med Chem 19:3893-9. 2012
  5. ncbi Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis
    Simone Mocellin
    Department of Oncological and Surgical Sciences, Meta analysis Unit, University of Padova, Padova, Italy
    J Natl Cancer Inst 104:840-54. 2012
  6. ncbi Peptides in melanoma therapy
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Curr Pharm Des 18:820-31. 2012
  7. ncbi Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival
    Loris Bertazza
    Department of Oncological and Surgical Sciences, Section of Clinica Chirurgica 2, University of Padova, Via Giustiniani 2, 35128, Padua, Italy
    J Transl Med 7:111. 2009
  8. ncbi EUS for the staging of gastric cancer: a meta-analysis
    Simone Mocellin
    Meta analysis Unit, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Gastrointest Endosc 73:1122-34. 2011
  9. ncbi Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis
    Simone Mocellin
    Clinica Chirurgica Generale 2, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    J Natl Cancer Inst 102:493-501. 2010
  10. ncbi The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins
    Simone Mocellin
    Department of Oncological and Surgical Sciences, Meta analysis Unit, University of Padova, Via Giustiniani 2, Padua, Italy
    Ann Surg 253:238-43. 2011

Detail Information

Publications109 found, 100 shown here

  1. ncbi Coinhibitory molecules in cancer biology and therapy
    Simone Mocellin
    Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Cytokine Growth Factor Rev 24:147-61. 2013
    ....
  2. ncbi Vitamin D and cancer: deciphering the truth
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Biochim Biophys Acta 1816:172-8. 2011
    ....
  3. ncbi Telomerase and the search for the end of cancer
    Simone Mocellin
    Department of Surgery, Oncology, and Gastroenterology, School of Medicine, University of Padova, 35100 Padova, Italy
    Trends Mol Med 19:125-33. 2013
    ..Despite significant progress, issues remain to be addressed before telomerase-based therapies are truly effective and we include critical discussion of the results obtained thus far...
  4. ncbi Circumventing melanoma chemoresistance by targeting DNA repair
    S Mocellin
    Department Oncological and Surgical Sciences, University of Padova, Italy
    Curr Med Chem 19:3893-9. 2012
    ..In this review we summarize the experimental and clinical findings that are fostering the research in this promising field of oncology...
  5. ncbi Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis
    Simone Mocellin
    Department of Oncological and Surgical Sciences, Meta analysis Unit, University of Padova, Padova, Italy
    J Natl Cancer Inst 104:840-54. 2012
    ..We conducted a systematic review and meta-analysis of the available molecular epidemiology data regarding the association between TERT locus polymorphisms and predisposition to cancer...
  6. ncbi Peptides in melanoma therapy
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Curr Pharm Des 18:820-31. 2012
    ..I also discuss some immunological and methodological issues that might be helpful for the successful development of peptide-based vaccines...
  7. ncbi Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival
    Loris Bertazza
    Department of Oncological and Surgical Sciences, Section of Clinica Chirurgica 2, University of Padova, Via Giustiniani 2, 35128, Padua, Italy
    J Transl Med 7:111. 2009
    ..We investigated on whether the expression of CTC related genes adds any prognostic power to the TNM staging system in patients with gastric carcinoma...
  8. ncbi EUS for the staging of gastric cancer: a meta-analysis
    Simone Mocellin
    Meta analysis Unit, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Gastrointest Endosc 73:1122-34. 2011
    ..The role of EUS in the locoregional staging of gastric carcinoma is undefined...
  9. ncbi Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis
    Simone Mocellin
    Clinica Chirurgica Generale 2, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    J Natl Cancer Inst 102:493-501. 2010
    ..However, RCTs have yielded conflicting data on the effect of IFN-alpha on overall survival (OS)...
  10. ncbi The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins
    Simone Mocellin
    Department of Oncological and Surgical Sciences, Meta analysis Unit, University of Padova, Via Giustiniani 2, Padua, Italy
    Ann Surg 253:238-43. 2011
    ..To quantify the impact of excision margins on disease-specific survival of patients with primary cutaneous melanoma...
  11. ncbi Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology
    Simone Mocellin
    Clinica Chirurgica Generale 2, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    PLoS ONE 5:e11965. 2010
    ..As a consequence, we are witnessing a paradoxical situation where most hypotheses about the molecular and cellular biology of cancer remain clinically untested and therefore do not translate into a therapeutic benefit for patients...
  12. ncbi Targeting death receptors to fight cancer: from biological rational to clinical implementation
    S Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Italy
    Curr Med Chem 17:2713-28. 2010
    ..In addition, the results so far obtained in the clinical oncology setting as well as the issues to be faced while interfering with these pathways for therapeutic purposes will be overviewed...
  13. ncbi Oncomirs: from tumor biology to molecularly targeted anticancer strategies
    Simone Mocellin
    Dept Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Mini Rev Med Chem 9:70-80. 2009
    ....
  14. ncbi Cutaneous melanoma in situ: translational evidence from a large population-based study
    Simone Mocellin
    Department of Oncological Sciences, University of Padova, Padova, Italy
    Oncologist 16:896-903. 2011
    ..Cutaneous melanoma in situ (CMIS) is a nosologic entity surrounded by health concerns and unsolved debates. We aimed to shed some light on CMIS by means of a large population-based study...
  15. ncbi Validation of the prognostic value of lymph node ratio in patients with cutaneous melanoma: a population-based study of 8,177 cases
    Simone Mocellin
    Clinica Chirurgica Generale, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Surgery 150:83-90. 2011
    ..However, its independence from the standard prognostic system TNM has not been formally proven in a large series of patients...
  16. ncbi Sentinel node status prediction by four statistical models: results from a large bi-institutional series (n = 1132)
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Ann Surg 250:964-9. 2009
    ..To improve selection for sentinel node (SN) biopsy (SNB) in patients with cutaneous melanoma using statistical models predicting SN status...
  17. ncbi Peptide-based anticancer vaccines: recent advances and future perspectives
    S Mocellin
    Clinica Chirurgica Generale 2, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Curr Med Chem 16:4779-96. 2009
    ..This review will describe the most recent insights in the rational design of peptide-based cancer vaccines, as well as the challenges to successful anticancer immunotherapy based on these short amino acid chains...
  18. ncbi Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis
    Simone Mocellin
    Meta analysis Unit, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Cancer 113:2398-407. 2008
    ..The current findings prompt further investigation on this subject and indirectly support the hypothesis that sun exposure may have an antimelanoma effect through activation of the vitamin D system...
  19. ncbi Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, via Giustianiani 2, 35128 Padova, Italy
    Med Res Rev 28:413-44. 2008
    ..In addition, the latest therapeutic strategies devised to overcome tumor immune escape are described, with special regard to those entering clinical phase investigation...
  20. ncbi Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node biopsy for cutaneous melanoma
    S Pasquali
    Department of Oncological and Surgical Sciences, Surgery Branch, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Eur J Surg Oncol 37:675-80. 2011
    ..The negative predictive value (NPV) of this test, which might help identify low-risk patients who might be safely spared SN biopsy (SNB), has not been yet investigated...
  21. ncbi Hypoxic antiblastic stop-flow perfusion: clinical outcome and pharmacokinetic findings
    D Miotto
    Department of Oncological and Surgical Sciences, University of Padova, Italy
    J Chemother 16:44-7. 2004
    ..In conclusion, SFP is a feasible procedure. Toxicity and tumor response rates strictly depend upon drug leakage control...
  22. ncbi Validation of the new AJCC TNM staging system for gastric cancer in a large cohort of patients (n = 2,155): focus on the T category
    A Marchet
    Clinica Chirurgica II, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Eur J Surg Oncol 37:779-85. 2011
    ..The aim of the present study was to validate the prognostic significance of the new T categorization within the frame of the latest TNM staging system...
  23. ncbi TNF-based limb perfusion for cutaneous melanoma in transit metastases: suggestions for modification of the perfusional schedule
    C R Rossi
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    J Exp Clin Cancer Res 22:103-7. 2003
    ..Our results showed that it is possible to modify the perfusion schedule, without compromising the response rate but with lower cost and toxicity...
  24. ncbi Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma
    Pierluigi Pilati
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Italy
    Ann Surg Oncol 10:508-13. 2003
    ..These findings support the conduction of formal phase III randomized trials...
  25. ncbi IL-10 stimulatory effects on human NK cells explored by gene profile analysis
    S Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy
    Genes Immun 5:621-30. 2004
    ....
  26. ncbi Hyperthermic isolated perfusion with low-dose TNFalpha and doxorubicin in patients with locally advanced soft tissue limb sarcomas
    C R Rossi
    Clinica Chirurgica II, University of Padova, Italy
    J Chemother 16:58-61. 2004
    ..Systemic side effects were negligible. The perfusate/plasma area under the curve (AUC) ratio for TNFalpha was 56. HILP with low-dose TNFalpha and DXR proved to be an active neoadjuvant drug regimen against limb-threatening STS...
  27. ncbi The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series
    A Marchet
    Clinica Chirurgica II, University of Padova, Padova, Italy
    Eur J Surg Oncol 34:159-65. 2008
    ..In the present work we validated the reliability of N-ratio in a large, multicenter series...
  28. ncbi Sentinel node biopsy and ultrasound scanning in cutaneous melanoma: clinical and technical considerations
    C R Rossi
    Dipartimento di Scienze Oncologiche e Chirurgiche, Sezione di Clinica Chirurgica II, Universita degli Studi di Padova, Via Giustiniani 2, 35128, Padova, Italy
    Eur J Cancer 36:895-900. 2000
    ..Breslow thickness and the number of metastatic SN(s), but not their type, are correlated with disease spread; CP10S contributed to the differentiation amongst the nodes and the determining of procedure's completion...
  29. ncbi Multimodal treatment of peritoneal carcinomatosis and sarcomatosis
    P Pilati
    Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, Padova, Italy
    Eur J Surg Oncol 27:125-34. 2001
    ....
  30. ncbi Treatment options for liver metastases from colorectal cancer
    M Lise
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    J Exp Clin Cancer Res 22:149-56. 2003
    ..Both systemic and locoregional chemotherapy might be useful in the neoadjuvant setting to increase the resectability of liver metastases initially not amenable to surgical resection...
  31. ncbi Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma
    Simone Mocellin
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padua, Padua, Italy
    Int J Cancer 107:317-22. 2003
    ....
  32. ncbi N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma
    Carlo Riccardo Rossi
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128, Padova, Italy
    Ann Surg Oncol 15:310-5. 2008
    ..In this study, we tested the hypothesis that the ratio between metastatic and excised lymph nodes ("N-ratio") might have an independent prognostic value in patients with TNM stage-III cutaneous melanoma...
  33. ncbi Gene expression profile of primary gastric cancer: towards the prediction of lymph node status
    Alberto Marchet
    Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, Istituto Oncologico Veneto IRCCS and University of Padova, Padova, Italy
    Ann Surg Oncol 14:1058-64. 2007
    ..The aim of this study was to screen the genome in the search of primary gastric cancer gene expression profiles that might predict lymph node status...
  34. ncbi Isolated limb perfusion in locally advanced cutaneous melanoma
    Carlo Riccardo Rossi
    Department of Surgical and Oncological Sciences Clinica Chirurgica II, University of Padova, Padova, Italy
    Semin Oncol 29:400-9. 2002
    ..As potential agents to be delivered through ILP, new vasoactive drugs and agents with new mechanisms of action that interplay with chemotherapy, as well as virus-mediated gene therapy, are being developed...
  35. ncbi Prognostic value of subclassification of T2 tumours in patients with gastric cancer
    D Nitti
    Clinica Chirurgica II, Department of Oncological and Surgical Sciences, University of Padua, Italy
    Br J Surg 96:398-404. 2009
    ..This study was designed to evaluate the prognostic value of tumour stage T2 subcategorization (T2a and T2b) in patients with gastric carcinoma...
  36. ncbi Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis
    Simone Mocellin
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Italy
    J Clin Oncol 25:1588-95. 2007
    ..However, no consensus exists on the clinical implementation of this prognostic indicator for the management of these patients...
  37. ncbi Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma
    Simone Mocellin
    Department of Oncologic and Surgical Sciences, University of Padua, Padua, Italy
    Int J Cancer 111:741-5. 2004
    ..Therefore, CTC detection might be employed for the selection of patients for adjuvant treatment and during follow-up for early indication of therapeutic failure...
  38. ncbi Electrochemotherapy for disseminated superficial metastases from malignant melanoma
    L G Campana
    Sarcoma and Melanoma Unit, Veneto Region Oncology Research Institute IOV IRCCS, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Br J Surg 99:821-30. 2012
    ..The aim of the study was to determine predictive factors for effectiveness, toxicity and local disease control in patients with malignant melanoma treated with bleomycin-based electrochemotherapy (ECT)...
  39. ncbi Overall survival in BRCA-associated ovarian cancer: case-control study of an Italian series
    G Artioli
    Department of Medical Science, Oncology Haematology Department, Mirano Venice, Veneto Oncology Istitute I O V, Padova, Italy
    Eur J Gynaecol Oncol 31:658-61. 2010
    ..The two groups showed similar characteristics concerning age at diagnosis, histological type and stage. Grade 3 was more frequent in the BRCA group. Survival data did not show any advantage for the BRCA mutated group...
  40. ncbi Hyperthermic isolated liver perfusion for unresectable liver cancers: pilot study
    M Lise
    Department of Oncological and Surgical Sciences, University of Padova, Italy
    J Chemother 16:37-9. 2004
    ..Locoregional toxicity was significant, which underscores the need for a more accurate preoperative evaluation of hepatic function...
  41. ncbi Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities
    C R Rossi
    Clinica Chirurgica II, University of Padova, Padova, Italy
    Melanoma Res 13:293-7. 2003
    ..The trial was then interrupted due to the low tolerability and poor efficacy of this perfusion regimen. At present, F ILP after DTIC chemosensitization should not be recommended for the treatment of locally advanced limb melanoma...
  42. ncbi The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients
    Alberto Marchet
    Clinica Chirurgica Generale 2, University of Padova, Padova, Italy
    Ann Surg 245:543-52. 2007
    ....
  43. ncbi Part I: Vaccines for solid tumours
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Italy
    Lancet Oncol 5:681-9. 2004
    ....
  44. ncbi The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis
    Simone Mocellin
    Department of Oncological and Surgical Sciences, Surgery Branch, University of Padova, Padua, Italy
    Clin Cancer Res 12:4605-13. 2006
    ..We aimed to comprehensively and quantitatively summarize the evidence for the use of CTC to predict patients' clinical outcome...
  45. ncbi Support vector machine learning model for the prediction of sentinel node status in patients with cutaneous melanoma
    Simone Mocellin
    Clinica Chirurgica 2, Dipartimento di Scienze Oncologiche e Chirurgiche, Universita di Padova, Via Giustiniani, 2, 35128 Padova, Italy
    Ann Surg Oncol 13:1113-22. 2006
    ..In this study, the predictive power of support vector machine (SVM)-based statistical analysis was tested...
  46. ncbi Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases : personal experience and literature meta-analysis
    Sandro Pasquali
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Cancer 116:1201-9. 2010
    ..It is debated whether patients with melanoma who undergo lymphadenectomy after a positive sentinel lymph node (SN) biopsy (SNB) have a better prognosis compared with patients who are treated for clinically evident disease...
  47. ncbi Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches
    Simone Mocellin
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padua, Italy
    Cancer Treat Rev 32:9-27. 2006
    ..In this work, we review the state-of-the-art of conventional treatments for STS and summarize the most promising findings in the development of molecularly targeted therapeutic approaches...
  48. ncbi Cancer vaccines: the challenge of developing an ideal tumor killing system
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Front Biosci 10:2285-305. 2005
    ....
  49. ncbi Cancer resistance to type II topoisomerase inhibitors
    P Pilati
    Department of Oncological and Surgical Sciences, University of Padova, Italy
    Curr Med Chem 19:3900-6. 2012
    ....
  50. ncbi [Adjuvant chemotherapy after radical liver resection in the treatment of metastases from colorectal carcinoma]
    E Mammano
    Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, Universita di Padova, Padova, Italia
    Minerva Chir 64:457-63. 2009
    ....
  51. ncbi Early detection of melanoma: an educational campaign in Padova, Italy
    C R Rossi
    Clinica Chirurgica II, Universita di Padova, Italy
    Melanoma Res 10:181-7. 2000
    ..0 mm versus 1.50 mm; P < 0.02)...
  52. ncbi Recent advances in conventional and molecular prognostic factors for gastric carcinoma
    Donato Nitti
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Surg Oncol Clin N Am 17:467-83, vii. 2008
    ....
  53. ncbi Hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from gastric adenocarcinoma
    Carlo Riccardo Rossi
    Department of Oncological and Surgical Sciences, Clinica Chirurgica II, University of Padua, Italy
    Suppl Tumori 2:S54-7. 2003
    ..Patients with peritoneal carcinomatosis from gastric carcinoma have a dismal prognosis. Hyperthermic intraperitoneal intraoperative chemotherapy (HIIC) has been proposed to treat residual disease after cytoreductive surgery...
  54. ncbi Role of resection margins in patients treated with breast conservation surgery
    Giorgio Zavagno
    Clinica Chirurgica II, University of Padova, Padova, Italy
    Cancer 112:1923-31. 2008
    ..The aim of this study was to investigate how margin status and other clinicopathologic factors correlate with the presence of residual tumor at reexcision...
  55. ncbi TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial
    Carlo Riccardo Rossi
    Department of Surgical and Oncological Sciences, Surgery Branch, University of Padua, Padua, Italy
    Ann Surg Oncol 15:1218-23. 2008
    ..However, most patients will ultimately experience disease recurrence. The aim of this pilot study was to test the hypothesis that systemic low-dose interferon alpha-2b (LDI) might consolidate the therapeutic effect of ILP...
  56. ncbi Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node
    Carlo Riccardo Rossi
    Department of Oncological and Surgical Sciences, Surgery Branch, University of Padova, Via Giustiniani 2, 35128, Padova, Italy
    Ann Surg Oncol 15:1202-10. 2008
    ..This study tested the hypothesis that the microscopic features of metastatic SLNs might predict not only nonsentinel lymph node (NSLN) status, but also patients' clinical outcomes...
  57. ncbi The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients
    Carlo Riccardo Rossi
    Department of Oncological and Surgical Sciences, Istituto di Clinica Chirurgica Generale II, Padova, Italy
    J Surg Oncol 83:80-4. 2003
    ..To evaluate the efficacy of preoperative ultrasound (US) scanning in identifying lymph node metastasis before sentinel node biopsy (SNB), we conducted a prospective study on 125 patients with primary cutaneous melanoma (CM)...
  58. ncbi Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients
    Carlo Riccardo Rossi
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Padua, Italy
    Cancer 100:1943-50. 2004
    ..After a Phase I study on cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy (HIIC), the authors reported the results of the treatment of 60 patients using this novel multimodal approach...
  59. ncbi Suppressive influences in the immune response to cancer
    Vincenzo Bronte
    Istituto Oncologico Veneto, Fondazione IRCCS, Padova, Italy
    J Immunother 32:1-11. 2009
    ..In this review, the best characterized mechanisms that allow cancer cells to evade immune surveillance are overviewed and the most debated controversies constellating this complex field are highlighted...
  60. ncbi Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study
    Carlo R Rossi
    Dipartimento di Scienze Oncologiche e Chirurgiche, Sezione Clinica Chirurgica Generale II, Universita di Padova, Italy
    Cancer 94:492-9. 2002
    ..To evaluate whether this regimen could be used for other tumor types, the authors conducted a Phase I study on HIIC with doxorubicin and cisplatin in patients with peritoneal carcinomatosis or sarcomatosis...
  61. ncbi Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines
    Simone Mocellin
    Clinica Chirurgica Generale II, Dipartimento di Scienze Oncologiche e Chirurgiche, Universita di Padova, Via Giustiniani 2, 35128 Padua, Italy
    Biochim Biophys Acta 1653:61-71. 2003
    ..The hypothesized role of innate immunity in predetermining tumor responsiveness to immunotherapeutic manipulation is also discussed...
  62. ncbi Pharmacokinetics of intraperitoneal cisplatin and doxorubicin
    Carlo Riccardo Rossi
    Surgery Branch, Department of Oncological and Surgical Science, University of Padova, Via Giustiniani, 2 35128 Padova, Italy
    Surg Oncol Clin N Am 12:781-94. 2003
    ..Likewise, liposomes, which in animal models seem to favor tumor uptake of encapsulated DXR, should now be tested in the clinical setting...
  63. ncbi Adjuvant immunotherapy for solid tumors: from promise to clinical application
    Simone Mocellin
    Department of Oncological and Surgical Sciences, Institute of Clinical Surgery II, 6 Piano Policlinico Uviversitario, Via Giustiniani 2, University of Padua, Padua, Italy
    Cancer Immunol Immunother 51:583-95. 2002
    ..Here, we review the immunological strategies so far explored in humans and report worldwide results following the clinical application of adjuvant immunotherapy for solid tumors...
  64. ncbi Gastrointestinal stromal tumors: from a surgical to a molecular approach
    Carlo Riccardo Rossi
    Department of Oncologic and Surgical Sciences, University of Padua, Padua, Italy
    Int J Cancer 107:171-6. 2003
    ..Molecular targeting of the critical pathogenetic mechanism underlying GIST might not only revolutionize the strategy to treat locally advanced and metastatic GIST but also improve disease control after macroscopically radical surgery...
  65. ncbi Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases
    Carlo Riccardo Rossi
    Clinica Chirurgica Generale II, Dipartimento di Scienze Oncologiche e Chirurgiche, Universita di Padova, Padova, Italy
    Ann Surg Oncol 11:173-7. 2004
    ..We here report on the results of L-PAM and low-dose tumor necrosis factor (TNF)alpha HILP in patients with bulky disease...
  66. ncbi TNF and cancer: the two sides of the coin
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Front Biosci 13:2774-83. 2008
    ....
  67. ncbi RNA interference: ready to silence cancer?
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padua, Italy
    J Mol Med (Berl) 84:4-15. 2006
    ....
  68. ncbi Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas
    Carlo Riccardo Rossi
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy
    Ann Surg Oncol 12:398-405. 2005
    ..The aim of this study was to investigate the anticancer activity of a novel drug regimen including doxorubicin (DXR) and low-dose TNF-alpha...
  69. ncbi Priming anticancer active specific immunotherapy with dendritic cells
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Curr Opin Investig Drugs 6:576-81. 2005
    ....
  70. ncbi Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases
    Pierluigi Pilati
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Oncol Rep 12:895-901. 2004
    ..Toxicity and tumor response rates strictly depend upon drug leakage control. Further efforts should be made to exploit the potential anti-tumor activity of this novel locoregional drug delivery system...
  71. ncbi Melanoma - what is new in sentinel node biopsy and locoregional treatments in 2003? Report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003
    Carlo Riccardo Rossi
    Universita di Padova, Dipartimento di Scienze Oncologiche e Chirurgiche, Sezione di Clinica Chirurgica II, Via Giustiniani, 2, 35128 Padova, Italy
    Melanoma Res 14:329-32. 2004
    ..The main comments made by the respective rapporteurs are also summarized...
  72. ncbi The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI)
    Carlo Riccardo Rossi
    Clinica Chirurgica 2, Universita di Padova, Padova, Italy
    J Nucl Med 47:234-41. 2006
    ..We report herein the results of this trial. The influence of some technical aspects on the outcome of SNB was also investigated, because a certain degree of variability was accepted in performing lymphoscintigraphy...
  73. ncbi Separate cavity margins excision as a complement to conservative breast cancer surgery
    G Zavagno
    Clinica Chirurgica II Breast Unit, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Eur J Surg Oncol 36:632-8. 2010
    ..However, approximately half of these patients have no residual tumour in the re-excision specimen. The aim of this study was to investigate if separate cavity margin (CM) excision can safely reduce the need of re-operation...
  74. ncbi Stop-flow technique for loco-regional delivery of antiblastic agents: literature review and personal experience
    P Pilati
    Department of Oncological and Surgical Sciences, Clinica Chirurgica Generale II, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Eur J Surg Oncol 28:544-53. 2002
    ..CONCLUSIONS: At present, the SF technique should be considered an investigational approach to locally advanced cancers. The encouraging results obtained with this procedure should be validated by large phase III trials...
  75. ncbi Tumor necrosis factor, cancer and anticancer therapy
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Policlinico Universitario, 6 piano, Via Giustiniani, 2, 35128 Padova, Italy
    Cytokine Growth Factor Rev 16:35-53. 2005
    ..Recent insights that might pave the way to further exploitation of the antineoplastic potential of TNF are also discussed...
  76. ncbi TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends
    Carlo Riccardo Rossi
    Department of Oncological and Surgical Sciences, University of Padova, Italy. carlor.rossi2unipd.it
    J Immunother (1997) 26:291-300. 2003
    ..The potential future developments of this locoregional therapeutic approach will also be reported...
  77. ncbi Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer
    Grazia Artioli
    Medical Oncology Department, Istituto Oncologico Veneto IRCCS, Via Gattamelata 64, 35128 Padova, Italy
    Anticancer Res 30:3817-21. 2010
    ..This was a phase II study to assess the activity of a novel neoadjuvant regimen in locally-advanced breast cancer...
  78. ncbi DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis
    Simone Mocellin
    Department of Oncological and Surgical Sciences, Meta analysis Unit, University of Padova, Padova, Italy
    Carcinogenesis 30:1735-43. 2009
    ....
  79. ncbi Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment
    Simone Mocellin
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    J Immunol Methods 280:1-11. 2003
    ..In vivo findings support the hypothesis that, after TNFalpha-based treatment, a Th1-type shift occurs in the tumor microenvironment...
  80. ncbi Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma
    Pierluigi Pilati
    Department of Oncological and Surgical Sciences, Istituto di Clinica Chirurgica Generale II, University of Padova, 6th Piano, Via Giustiniani, 2 35128, Padova, Italy
    World J Surg 27:640-6. 2003
    ..From these findings, it appears that heat sensitizes tumor cells-but not normal mucosa-to DXR activity. Furthermore, protein levels of TPI2 alpha in pretreatment samples could predict tumor sensitivity to DXR...
  81. ncbi Part II: Vaccines for haematological malignant disorders
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Italy
    Lancet Oncol 5:727-37. 2004
    ....
  82. ncbi Induction of endothelial nitric oxide synthase expression by melanoma sensitizes endothelial cells to tumor necrosis factor-driven cytotoxicity
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Clin Cancer Res 10:6879-86. 2004
    ..We investigated the role of endothelial nitric oxide synthase in determining the tumor-selective activity of TNF...
  83. ncbi Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients
    Luca G Campana
    Department of Oncological and Surgical Sciences, Istituto di Clinica Chirurgica Generale II, Policlinico Universitario, 6 degrees Piano Via Giustiniani 2, 33128, Padova, Italy
    Ann Surg Oncol 16:191-9. 2009
    ..This benefit, although preliminary, deserves further assessment after a formal validation of the dedicated questionnaire...
  84. ncbi Tumor immunology
    Simone Mocellin
    Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, University of Padova, Via Giustiniani 2, Italy
    Adv Exp Med Biol 593:147-56. 2007
    ..In the present Chapter, we report on some of the most significant results obtained with the application of DNA microarray in this oncology field...
  85. ncbi Use of laser scanning cytometry to study tumor microenvironment
    S Mocellin
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Italy
    Histol Histopathol 18:609-15. 2003
    ....
  86. ncbi Tumor necrosis factor (TNF) biology and cell death
    Loris Bertazza
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Front Biosci 13:2736-43. 2008
    ..Understanding this mechanism will not only shed new light on the physiological significance of TNF-driven programmed cell death but also help investigators maximize the anticancer potential of this cytokine...
  87. ncbi True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function
    Pierluigi Pilati
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128, Padova, Italy
    World J Surg 28:775-81. 2004
    ..These findings support the use of true hyperthermia in the clinical setting to exploit fully the antitumor synergism between melphalan and heat...
  88. ncbi Circulating tumor cells in solid cancer: tumor marker of clinical relevance?
    Loris Bertazza
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Curr Oncol Rep 10:137-46. 2008
    ..Confirming the prognostic value of CTC would provide clinicians with a unique tool for better stratification of patients' risk and provide basic researchers with a new target for the development of novel therapeutic approaches...
  89. ncbi New strategies to improve the efficacy of colorectal cancer vaccines: from bench to bedside
    Simone Mocellin
    University of Padova, Department of Oncological and Surgical Sciences, Via Giustiniani 2, 35128 Padova, Italy
    Curr Opin Investig Drugs 7:1052-61. 2006
    ....
  90. ncbi Cancer vaccine development: on the way to break immune tolerance to malignant cells
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Italy
    Exp Cell Res 299:267-78. 2004
    ....
  91. ncbi Metabolic immune restraints: implications for anticancer vaccines
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Curr Pharm Des 16:277-91. 2010
    ..These mechanistic insights are fostering the development of rationally designed therapeutics aimed to revert the immunosuppressive circuits and thus to enhance the effectiveness of anticancer vaccines...
  92. ncbi Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease
    Simone Mocellin
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128, Padova, Italy
    Ann Surg Oncol 14:802-9. 2007
    ....
  93. ncbi Nitric oxide: cancer target or anticancer agent?
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, Padua, Italy
    Curr Cancer Drug Targets 9:214-36. 2009
    ..Accordingly, only an in depth knowledge of the mechanisms leading to experimental tumor regression or progression in response to NO will allow us to exploit this molecule to fight cancer...
  94. ncbi Colorectal cancer vaccines: principles, results, and perspectives
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, 35128 Padova, Italy
    Gastroenterology 127:1821-37. 2004
    ..We also discuss the most recent preclinical tumor immunology insights that might change the way to design the next generation of cancer vaccines, hopefully improving the effectiveness of such a biotherapeutic approach...
  95. ncbi Strategies to enhance the anticancer potential of TNF
    Pierluigi Pilati
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Front Biosci 13:3181-93. 2008
    ..This would enhance the anticancer activity of current TNF-based locoregional regimens and would pave the way to the systemic administration of this cytokine and thus to a much wider clinical experimentation of TNF in the oncology field...
  96. ncbi Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities
    Simone Mocellin
    Department of Oncological and Surgical Sciences, School of Medicine, University of Padova, Padova, Italy
    Med Res Rev 27:317-52. 2007
    ....
  97. ncbi Quantitative real-time PCR: a powerful ally in cancer research
    Simone Mocellin
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Trends Mol Med 9:189-95. 2003
    ..Knowledge of the biochemical principles underlying this biotechnology can be of great value to interpret correctly qrt-PCR data...
  98. ncbi Tumor microenvironment: what have we learned studying the immune response in this puzzling battlefield?
    Simone Mocellin
    Immunnogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Tumori 88:437-44. 2002
    ..As a model, we will discuss the observed immune response to tumor antigen -specific immunization and its relationship with the systemic administration of IL-2...
  99. ncbi Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178
    Maria P Bettinotti
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 105:210-6. 2003
    ..Because of the modest immunological and clinical results, the present protocol has been discontinued as new routes of administration are being considered...
  100. ncbi [Trends in colorectal cancer vaccination]
    Simone Mocellin
    Sezione di Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, Universita, Padova
    Recenti Prog Med 96:338-43. 2005
    ....
  101. ncbi Cancer vaccines: pessimism in check
    Simone Mocellin
    Nat Med 10:1278-9; author reply 1279-80. 2004